Please assess the completion status of the following clinical trial:

Trial Title: Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with diagnosis of mild AD~Exclusion Criteria:~* Concomitant or previous treatment by acetylcholinesterase inhibitors and/or memantine~* Medical condition which may interfere with the study~* History of epileptic seizures~* Lens opacity~* Lack of reliable caregiver~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): dose 1
- 2 (Type: EXPERIMENTAL): dose 2
- 3 (Type: EXPERIMENTAL): dose 3
- 4 (Type: PLACEBO_COMPARATOR): None
- 5 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).